TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01800370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draws
Description: Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draws
Description: Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood Draws
Description: Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting procedure
Description: Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
Study: NCT01936610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lecture
Description: Describe advantages and disadvantages in one 90-min session
Study: NCT01800370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting procedure
Description: Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fasting procedure
Description: Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
Study: NCT02103075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.
Study: NCT02907372

Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychologic evaluation

Intervention type: OTHER
Group type: OTHER
Intervention: oncogeriatric evaluation
Study: NCT02114684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: \[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)\]
Study: NCT01409278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration and infusion.
Description: 50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
Study: NCT03945422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuTite/FaceTite
Description: Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
Study: NCT03287310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3511294
Description: GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.
Study: NCT04728256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter therapy+Music listening+Keeping diary
Description: Laughter therapy was carried out by the researcher as a total of three sessions every 15 days, and each session lasted 30 minutes.~Participants listened to the types of music that they like (pop, Turkish folk music). In the meeting room in FHC, Two professional artists performed music recitals with a guitar and saz (qopuz) to pregnant women, and pregnant women actively participated in this process. The performance was carried out as three sessions, once every 15 days, and each session took 40 minutes.~In addition to music listening and laughter therapy, the pregnant women were asked to keep a diary to write down their emotions about their health status, pregnancy and baby. Then, each participant had an opportunity to explain her emotions or replies to the questions during the group therapy sessions every 15 days so that pregnant women were able to express their feelings.
Study: NCT02883556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
Study: NCT04192331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel regimen1
Description: nab-paclitaxel regimen1 means use abraxine with 125mg/m2 at day 1 and day 8 per 21d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel regimen2
Description: nab-paclitaxel regimen2 means use abraxine with 125mg/m2 at day 1 and day 8 and day 15 per 28d.
Study: NCT01495988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
Study: NCT04685811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron
Description: 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron; single dose each, approximately 100-300 mBq.
Study: NCT01680913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
Study: NCT01495988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
Study: NCT03780595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Passiflora incarnata
Description: Passiflora pills administration up to 6 pills per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control pills administration up to 6 pills per day
Study: NCT05107245

Intervention type: DIAGNOSTIC_TEST
Intervention: 1test1
Description: Loss of bacterial diversity diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: 1test1
Description: Loss of bacterial diversity diagnosis
Study: NCT01495988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobimetinib
Description: Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
Study: NCT05766579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic-compressive stockings
Description: Use of Elastic-compressive stockings at 21 mmHg and 32 mmHg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic-compressive stockings
Description: Use of Elastic-compressive stockings at 21 mmHg and 32 mmHg.
Study: NCT03747445

Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass
Description: laparoscopic surgical procedure
Study: NCT03234335

Intervention type: OTHER
Intervention: Data collection
Description: Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.
Study: NCT01680913

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palpation of Tuffier's line
Description: Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthetic
Description: Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthetic
Description: Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
Study: NCT02761538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AVIITAM
Description: The purpose of the project is to test the medico economic impact related to the utilization of the Aviitam online platform in primary care.~.~.
Study: NCT02757014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number - R84-087)
Study: NCT02990962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Description: Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1cc 2% Xylocaine+4cc Triamcinolone (40mg)
Description: Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
Study: NCT00191100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study: NCT00678717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autonomic Evaluation
Description: Orthostatic vital signs will be determined by measuring heart rate (HR) and brachial blood pressure (BP) during a tilt table test. The degree of vagal mediated sinus arrhythmia will be assessed during controlled breathing (5 seconds inhalation and 5 seconds exhalation during 90 seconds), and the sinus arrhythmia parameters will be calculated as the difference and ratio of the longest to the shortest RR interval. The sympathetic response during breath hold will be measured. Responses of BP, HR, MSNA will be acquired during Valsalva maneuver. The valsalva ratio of heart rate will be calculated from the maximum of heart rate during or shortly after straining and the minimal depressed heart rate in the overshoot phase IV. Blood pressure and MSNA increase during isometric handgrip maintained at 30% of maximal voluntary contraction for five minutes will be determined. The blood pressure and MSNA response will be measured during cold pressor test with the hand in ice water for 1 minute.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autonomic Evaluation
Description: Orthostatic vital signs will be determined by measuring heart rate (HR) and brachial blood pressure (BP) during a tilt table test. The degree of vagal mediated sinus arrhythmia will be assessed during controlled breathing (5 seconds inhalation and 5 seconds exhalation during 90 seconds), and the sinus arrhythmia parameters will be calculated as the difference and ratio of the longest to the shortest RR interval. The sympathetic response during breath hold will be measured. Responses of BP, HR, MSNA will be acquired during Valsalva maneuver. The valsalva ratio of heart rate will be calculated from the maximum of heart rate during or shortly after straining and the minimal depressed heart rate in the overshoot phase IV. Blood pressure and MSNA increase during isometric handgrip maintained at 30% of maximal voluntary contraction for five minutes will be determined. The blood pressure and MSNA response will be measured during cold pressor test with the hand in ice water for 1 minute.
Study: NCT00191100

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy, 30-35 Gy over 1 week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Brachytherapy, 30-35 Gy over 1 week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiation
Description: Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic radiation
Description: Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
Study: NCT02811159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone acetate
Description: Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.
Study: NCT01981057

Intervention type: OTHER
Intervention: Numeta
Description: parenteral receipt prescribed with Numeta
Study: NCT03395210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: BTK inhibitor
Study: NCT01854294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM604
Description: GM604 treated group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
Study: NCT01981057

Intervention type: OTHER
Intervention: Numeta
Description: parenteral receipt prescribed with Numeta

Intervention type: OTHER
Intervention: Individual
Description: parenteral receipt prescribed individually
Study: NCT01854294

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
Study: NCT03159650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravascular ultrasonography
Description: intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravascular ultrasonography
Description: intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
Study: NCT03524378

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ergonomic and movement modifications
Description: Introduction of basic ergonomic and self-management principles, participants will review video clips of the prioritized and revised solutions. Adjustments in work tasks, movement strategies or self-management techniques will be self selected by workers after an educational session using videotapes of work processes.
Study: NCT01059851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with \~240 mL of water after an 8 hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with \~240 mL of water after an 8 hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with \~240 mL of water after an 8 hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with \~240 mL of water after an 8 hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with \~240 mL of water after an 8 hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with \~240 mL of water after an 8 hour fast
Study: NCT00433290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo every day (QD), by mouth (PO) for 13 weeks
Study: NCT00817791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen pretreatment (GR2200)
Description: 2 hours/day,5 days before surgery
Study: NCT01895842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1.
Study: NCT03217097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy
Description: The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy
Description: The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alkylating-based chemotherapy
Description: The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alkylating-based chemotherapy
Description: The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week).
Study: NCT01981057

Intervention type: OTHER
Intervention: Individual
Description: parenteral receipt prescribed individually
Study: NCT04905498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercial Advertising Literacy Training
Description: Children were shown food commercials and in between those commercials they saw and heard statements such as These foods won't make you happy and Those foods are so unhealthy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Children were shown food commercials that were the same length as the other group but did not receive any information about whether the content was truthful.
Study: NCT01902771

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate
Description: Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
Study: NCT03672162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total abdominal hysterectomy
Description: Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total abdominal hysterectomy
Description: Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Total abdominal hysterectomy
Description: Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia